coumarin has been researched along with heparitin sulfate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Warkentin, TE | 1 |
| Greinacher, A; Krahn, EL; Lubenow, N; Magnani, HN; Sloane, DA; Warkentin, TE; Wessel, A | 1 |
1 review(s) available for coumarin and heparitin sulfate
| Article | Year |
|---|---|
An overview of the heparin-induced thrombocytopenia syndrome.
Topics: Antibodies; Anticoagulants; Cardiovascular Diseases; Coumarins; Heparin; Heparitin Sulfate; Humans; Immunoglobulin G; Models, Biological; Monocytes; Phenotype; Platelet Activation; Platelet Factor 4; Thrombin; Thrombocytopenia; Thrombosis | 2004 |
1 other study(ies) available for coumarin and heparitin sulfate
| Article | Year |
|---|---|
Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s.
Topics: Aged; Ancrod; Canada; Chondroitin Sulfates; Cohort Studies; Coumarins; Dermatan Sulfate; Female; Germany; Heparin; Heparitin Sulfate; Humans; Male; Outcome Assessment, Health Care; Platelet Count; Practice Patterns, Physicians'; Retrospective Studies; Survival Analysis; Thrombocytopenia | 2006 |